Fig. 1.
Fig. 1. Effect of chronic IL-12 on body weight (A) and food intake (B) and protection by anti–IFN-γ antibodies. IL-12 was administered at the dose of 400 ng/mouse intraperitoneally (IP), once daily; anti–IFN-γ antibodies were administered on days 1 and 3 (0.2 mL/mouse, IP). One group of mice received control antibodies (antihuman EGF receptor). Weight change was calculated based on the weight at the beginning of treatment and data are expressed as mean ± SD (n = 5). Food intake was evaluated per cage with five mice. (□), Vehicle; (♦), IL-12; (•), anti–IFN-γ + IL-12; (▵), control antibody + IL-12.

Effect of chronic IL-12 on body weight (A) and food intake (B) and protection by anti–IFN-γ antibodies. IL-12 was administered at the dose of 400 ng/mouse intraperitoneally (IP), once daily; anti–IFN-γ antibodies were administered on days 1 and 3 (0.2 mL/mouse, IP). One group of mice received control antibodies (antihuman EGF receptor). Weight change was calculated based on the weight at the beginning of treatment and data are expressed as mean ± SD (n = 5). Food intake was evaluated per cage with five mice. (□), Vehicle; (♦), IL-12; (•), anti–IFN-γ + IL-12; (▵), control antibody + IL-12.

Close Modal

or Create an Account

Close Modal
Close Modal